TELA Bio CEO Resigns; Heather Getz Appointed CEO with Equity Grants

What Happened
TELA Bio, Inc. filed an 8-K announcing that Antony Koblish will no longer serve as the company’s Chief Executive Officer and resigned from the Board effective August 3, 2026. The board appointed Heather Getz as Chief Executive Officer and as a Class II director (term expiring at the 2027 Annual Meeting), effective the same date. Koblish’s termination is being treated as a termination without cause; a separation agreement is expected but not yet finalized. The company also entered into an employment agreement with Ms. Getz and granted her initial equity awards as an inducement.

Key Details

• Effective date: August 3, 2026; Koblish resigned from the Board at 12:01 am ET on that date. Company states the change was not due to any disagreement over operations, policies or practices.
• Getz compensation: $650,000 annual base salary and 100% target cash bonus (prorated for 2026; 2026 bonus prorated with a 5/12 numerator).
• Severance & benefits: If terminated without “Cause” or for “Good Reason,” Getz gets 12 months’ severance (18 months in a change-of-control period), prorated/paid bonus amounts, and up to 12 months’ continued health coverage.
• Initial equity grants (Aug 3, 2026): options to buy 1,365,000 shares (standard) and 1,005,000 premium-priced options, plus 500,000 RSUs; typical 25% vest at 1 year then monthly or annual vesting; option expiry Aug 3, 2036. If the company raises equity within 18 months, additional “Top-Up Grants” will be issued so total grants equal 5% of outstanding shares post-financing.

Why It Matters
Leadership has changed at the top of TELA Bio, which can affect strategy and investor confidence. The new CEO brings extensive healthcare and med-tech experience, and her employment package includes substantial equity awards that could increase share dilution and future compensation expense. Investors should watch for the forthcoming separation agreement for Koblish (which may include cash or equity treatment) and any disclosures about Top-Up Grants following potential financings, as these items could materially affect shares outstanding and the company’s expense profile.